In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
- Advertisement -
Latest article
Dutch Queen promotes biobased building materials
In the Netherlands, Dutch Queen consort Máxima visited two Uden worksites promoting biobased building materials made from Netherlands fiber crops.
The March 26 visit...
ReefCircular launches crowdfunding campaign for shell bioconcrete
In Denmark, ReefCircular, a company developing a shell-based bioconcrete to help restore marine habitats, has launched a crowdfunding campaign on Kickstarter.
The company’s bioconcrete...
Aleph Farms raises $29 million for lab-grown steak
In Israel, cultivated meat producer Aleph Farms has raised $29 million to expand production at its Rehovot pilot plant and expand production into Europe...